search
Back to results

Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens

Primary Purpose

Myopia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
narafilcon B contact lens
nelfilcon A contact lens
lotrafilcon B contact lens
Sponsored by
Johnson & Johnson Vision Care, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myopia

Eligibility Criteria

18 Years - 39 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Be no less than 18 and no more than 39 years of age.
  • Sign Written Informed Consent and investigator to record this on Case Report Form (See separate document).
  • Be willing and able to adhere to the instructions set out in the protocol.
  • Own a cell phone and be willing to receive text messages during the day.
  • Be an existing successful daily wear soft contact lens. For the purposes of this study this means wearing lenses for at least 6 hours per day, 5 days per week for the last month.
  • No extended wear in the last 3 months.
  • Subjective refraction must result in a vertexed spherical contact lens prescription between -1.00 and -6.00D.
  • Have refractive astigmatism less than or equal to 1.00D in both eyes.
  • Achieve visual acuity of 6/9 (20/30) or better in each eye.
  • Require a visual correction in both eyes (no monofit or monovision allowed).
  • Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D).
  • Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
  • No amblyopia.
  • No evidence of lid abnormality or infection (including blepharitis/meibomitis).

    • No conjunctival abnormality or infection.
    • No clinically significant slit lamp findings (i.e. stromal edema, vascularization, infiltrates or abnormal opacities).
    • No other active ocular disease.

Exclusion Criteria:

  • Requires concurrent ocular medication.
  • Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
  • Clinically significant corneal staining (Grade 3 in more than one corneal region per eye).
  • Requires presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D).
  • Has had refractive surgery.
  • Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study.
  • Abnormal lacrimal secretions.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Keratoconus or other corneal irregularity.
  • PMMA(polymethyl methacrylate), hybrid or RGP(rigid gas permeable) lens wear in the previous 8 weeks.

Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D).

  • Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
  • Diabetic.
  • Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV (Human immunodeficiency virus)).
  • History of chronic eye disease (e.g. glaucoma or ARMD (age related macular degeneration)).
  • Pregnancy, lactating or planning a pregnancy at the time of enrolment.
  • Participation in any concurrent clinical trial or in last 30 days.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

narafilcon B daily disposable 4 weeks

nelfilcon A daily disponsable 1 week

lotrafilcon B daily wear, monthly replacement, 4-weeks

Arm Description

narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks

nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week

lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks

Outcomes

Primary Outcome Measures

Overall Comfort Narafilcon B v. Nelfilcon A
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A
Redness scale of 0 to 4, where 0=None, 4=Severe redness
Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B
Redness scale of 0 to 4, where 0=None, and 4=Severe.

Secondary Outcome Measures

Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A
Standard scale of 0 to 3 where 0=None, 3=Severe staining
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A
Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort
Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.
Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B
Scale of 0 to 3, where 0=none and 3=severe staining.
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B
Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort
Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.

Full Information

First Posted
March 24, 2010
Last Updated
June 18, 2018
Sponsor
Johnson & Johnson Vision Care, Inc.
Collaborators
Visioncare Research Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01151371
Brief Title
Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 1, 2010 (Actual)
Primary Completion Date
April 1, 2010 (Actual)
Study Completion Date
April 1, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johnson & Johnson Vision Care, Inc.
Collaborators
Visioncare Research Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of the study is to compare the clinical performance of silicone hydrogel daily disposable contact lenses, conventional hydrogel daily disposable contact lenses and silicone hydrogel monthly replacement contact lenses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
452 (Actual)

8. Arms, Groups, and Interventions

Arm Title
narafilcon B daily disposable 4 weeks
Arm Type
Experimental
Arm Description
narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
Arm Title
nelfilcon A daily disponsable 1 week
Arm Type
Active Comparator
Arm Description
nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
Arm Title
lotrafilcon B daily wear, monthly replacement, 4-weeks
Arm Type
Active Comparator
Arm Description
lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
Intervention Type
Device
Intervention Name(s)
narafilcon B contact lens
Intervention Description
Silicone Hydrogel Daily Disposable Contact Lenses
Intervention Type
Device
Intervention Name(s)
nelfilcon A contact lens
Intervention Description
Conventional Hydrogel Daily Disposable Contact Lenses
Intervention Type
Device
Intervention Name(s)
lotrafilcon B contact lens
Intervention Description
Silicone Hydrogel Monthly Replacement Contact Lenses
Primary Outcome Measure Information:
Title
Overall Comfort Narafilcon B v. Nelfilcon A
Description
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time Frame
After 1 week
Title
Signs of Limbal Hyperemia Narafilcon B v. Nelfilcon A
Description
Redness scale of 0 to 4, where 0=None, 4=Severe redness
Time Frame
After 1 Week
Title
Subjective Rating of Overall Comfort Narafilcon B v. Lotrafilcon B
Description
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time Frame
After 4 Weeks
Title
Signs of Limbal Hyperemia Narafilcon B v. Lotrafilcon B
Description
Redness scale of 0 to 4, where 0=None, and 4=Severe.
Time Frame
After 4 Weeks
Secondary Outcome Measure Information:
Title
Signs of Inferior Corneal Staining Narafilcon B v. Nelfilcon A
Description
Standard scale of 0 to 3 where 0=None, 3=Severe staining
Time Frame
After 1 Week
Title
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v Nelfilcon A
Description
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time Frame
After 1 Week
Title
Subjective Rating of End of Day Comfort Narafilcon B v. Nelfilcon A
Description
Scale of 1 to 5, where 1=Poor comfort and 5=Excellent comfort
Time Frame
After 1 Week
Title
Subjective Rating of Initial Comfort Narafilcon B v. Nelfilcon A
Description
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort.
Time Frame
After 1 Week
Title
Signs of Inferior Corneal Staining Narafilcon B v. Lotrafilcon B
Description
Scale of 0 to 3, where 0=none and 3=severe staining.
Time Frame
After 4 Weeks
Title
Subjective Rating of Overall Ease of Lens Handling Narafilcon B v. Lotrafilcon B
Description
Contact Lens User Experience (CLUE)TM questionnaire: A validated patient-reported outcomes questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response.
Time Frame
After 4 Weeks
Title
Subjective Rating of End of Day Comfort Narafilcon B v. Lotrafilcon B
Description
Scale of 1 to 5, where 1=poor comfort and 5=excellent comfort
Time Frame
After 4 Weeks
Title
Subjective Rating of Initial Comfort Narafilcon B v. Lotrafilcon B
Description
Comfort immediately after the lens is put on the eye. Scale of 1 to 5, where 1=poor comfort, 5=excellent comfort.
Time Frame
After 4 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be no less than 18 and no more than 39 years of age. Sign Written Informed Consent and investigator to record this on Case Report Form (See separate document). Be willing and able to adhere to the instructions set out in the protocol. Own a cell phone and be willing to receive text messages during the day. Be an existing successful daily wear soft contact lens. For the purposes of this study this means wearing lenses for at least 6 hours per day, 5 days per week for the last month. No extended wear in the last 3 months. Subjective refraction must result in a vertexed spherical contact lens prescription between -1.00 and -6.00D. Have refractive astigmatism less than or equal to 1.00D in both eyes. Achieve visual acuity of 6/9 (20/30) or better in each eye. Require a visual correction in both eyes (no monofit or monovision allowed). Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: No amblyopia. No evidence of lid abnormality or infection (including blepharitis/meibomitis). No conjunctival abnormality or infection. No clinically significant slit lamp findings (i.e. stromal edema, vascularization, infiltrates or abnormal opacities). No other active ocular disease. Exclusion Criteria: Requires concurrent ocular medication. Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear. Clinically significant corneal staining (Grade 3 in more than one corneal region per eye). Requires presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study. Abnormal lacrimal secretions. Pre-existing ocular irritation that would preclude contact lens fitting. Keratoconus or other corneal irregularity. PMMA(polymethyl methacrylate), hybrid or RGP(rigid gas permeable) lens wear in the previous 8 weeks. Does not require presbyopic correction (i.e. Not using any presbyopic correction and measured add power of less than +1.00D). Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. Diabetic. Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV (Human immunodeficiency virus)). History of chronic eye disease (e.g. glaucoma or ARMD (age related macular degeneration)). Pregnancy, lactating or planning a pregnancy at the time of enrolment. Participation in any concurrent clinical trial or in last 30 days.
Facility Information:
City
Brea
State/Province
California
Country
United States
City
Canoga Park
State/Province
California
Country
United States
City
Corona
State/Province
California
Country
United States
City
Bridgeport
State/Province
Connecticut
Country
United States
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32205
Country
United States
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Winter Park
State/Province
Florida
Country
United States
City
Roswell
State/Province
Georgia
Country
United States
City
Mishawaka
State/Province
Indiana
Country
United States
City
Boston
State/Province
Massachusetts
Country
United States
City
Blue Springs
State/Province
Missouri
Country
United States
City
Independence
State/Province
Missouri
Country
United States
City
Lake Ozark
State/Province
Missouri
Country
United States
City
New York
State/Province
New York
Country
United States
City
Raleigh
State/Province
North Carolina
Country
United States
City
Chagrin Falls
State/Province
Ohio
Country
United States
City
North Olmsted
State/Province
Ohio
Country
United States
City
Warren
State/Province
Ohio
Country
United States
City
Kittanning
State/Province
Pennsylvania
Country
United States
City
State College
State/Province
Pennsylvania
Country
United States
City
Warwick
State/Province
Rhode Island
Country
United States
City
Bartlett
State/Province
Tennessee
Country
United States
City
Brentwood
State/Province
Tennessee
Country
United States
City
Tyler
State/Province
Texas
ZIP/Postal Code
75701
Country
United States
City
Tyler
State/Province
Texas
ZIP/Postal Code
75703
Country
United States
City
Burlington
State/Province
Vermont
Country
United States
City
Virginia Beach
State/Province
Virginia
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens

We'll reach out to this number within 24 hrs